Safety · Source update
FDA proposes restricting three GLP-1 ingredients on 503B list
Source context: Read the linked original research or registry entry for study status and limitations.
The FDA proposed excluding semaglutide, tirzepatide and liraglutide from its 503B bulks list. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What happened?
In April 2026, FDA announced a proposal related to semaglutide, tirzepatide and liraglutide on the 503B bulks list. The regulatory question concerns circumstances in which registered outsourcing facilities may compound using bulk drug substances under a specific statutory framework.
What is a proposal versus a final decision?
A proposal explains an agency's intended action and the evidence supporting it, often with an opportunity for public comment. The April notice should not be described as though a final rule was already in force on the announcement date.
What is the practical patient issue?
Compounded drugs are not FDA-approved versions of the marketed medicines. They are not subject to the same premarket review for safety, effectiveness and manufacturing quality. FDA has separately warned about dosing errors and questionable online supply chains involving GLP-1 products.
Does this address every kind of pharmacy compounding?
No. The 503B outsourcing facility pathway differs from other applicable compounding provisions. The legal analysis turns on the precise product, facility and statutory conditions; simplified statements that 'all compounding is banned' are not supported by a proposal about the 503B bulks list.
Where should patients verify information?
Check FDA's current compounding guidance and the licensing status of any dispensing pharmacy. Do not rely on social media claims or unidentified vial concentrations when choosing a prescription product.
The bottom line
Distinguish proposed regulatory action from a final decision.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-04-30. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceFDA 503B bulks list proposal ↗
Source event or update: 2026-04-30. Our interpretation is educational and does not replace medical or insurance advice.